Journal of Virology & Antiviral ResearchISSN: 2324-8955

Research Article, J Virol Antivir Res Vol: 2 Issue: 3

Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population

Mackenzie Cottrell2, R Chris Rathbun1, Ryan Webb1, Pete Johnson1 and Staci M Lockhart1*
1College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, USA
2Department of Experiential Education, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma 73117, USA
Corresponding author : Staci M Lockhart
1110 N. Stonewall Avenue, College of Pharmacy, Room 223, Oklahoma City, Oklahoma 73117, USA
Tel: 405-271-6878 (Ext: 47369); Fax: 405-271-6430
E-mail: [email protected]
Received: August 19, 2013 Accepted: September 11, 2013 Published: September 13, 2013
Citation: Cottrell M, Rathbun RC, Webb R, Johnson P, Lockhart SM, et al. (2013) Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population. J Virol Antivir Res 2:3. doi:10.4172/2324-8955.1000114

Abstract

Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population

Morbidity and mortality rates from chronic liver disease secondary to hepatitis C virus (HCV) have become a significant issue for HIV infected patients. U.S. Department of Health and Human Service guidelines recommend HCV treatment for all coinfected patients without decompensated liver disease. Telaprevir and boceprevir are direct-acting agents (DAAs) recently approved for HCV genotype-1 mono-infection and have demonstrated marked improvements in viral suppression when combined with peg-interferon/ribavirin as triple therapy. Identification of co-infected patients who could benefit from HCV treatment is a necessary component of quality HIV care.

Keywords:

Track Your Manuscript

Share This Page

Media Partners